News

Press Releases

Below you will find a list of LEO Pharma's most recent global and affiliate-issued press releases, relevant to LEO Pharma Inc., LEO Pharma’s U.S. business. These press releases are intended for use by media. Please note that you will be linking out to the LEO Pharma global website or the news wire to access these press releases.  
 
7-9-20 LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis​

6-29-20 NJ.com Recognizes LEO Pharma Inc. as a New Jersey Top Workplace 2020​

6-12-20 LEO Pharma Presents Results From Study of Twice-Weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for Topical Use in Long-Term Maintenance Treatment of Plaque Psoriasis

6-12-20
 Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis

6-02-20 LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the AAD Virtual Meeting Experience 2020

4-28-20 LEO Pharma Inc. Donates $25,000 to New Jersey Pandemic Relief Fund   

4-15-20 LEO Pharma Inc. Announces Availability of Finacea® (azelaic acid) Foam, 15%, for Treatment of Mild-to-Moderate Rosacea

3-15-20 Update from LEO Pharma Inc. on COVID-19​

12-11-19 LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD

8-27-19 LEO Pharma Files IND Application to FDA for a Clinical Study of JW1601/LP0190 in the US

8-1-19 LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis

6-3-2019 LEO Pharma appoints Catherine Mazzacco as new CEO


5-10-2019 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management

4-9-2019 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology

Visit the LEO Pharma global news page for additional press releases of interest.